Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar 22;8(44):75864-75873.
doi: 10.18632/oncotarget.16439. eCollection 2017 Sep 29.

A nation-wide multicenter 10-year (1999-2008) retrospective study of chemotherapy in Chinese breast cancer patients

Qiao Li  1 , Zhao Yang  2 , Jinhu Fan  2 , Jianjun He  3 , Bin Zhang  4 , Hongjian Yang  5 , Xiaoming Xie  6 , Zhonghua Tang  7 , Hui Li  8 , Youlin Qiao  2 , Pin Zhang  1
Affiliations

A nation-wide multicenter 10-year (1999-2008) retrospective study of chemotherapy in Chinese breast cancer patients

Qiao Li et al. Oncotarget. .

Abstract

Little information is available on the evolvement of chemotherapeutic regimens administered to Chinese females with breast cancer. We retrospectively analyzed demographic, pathological and chemotherapeutic data of 4211 breast cancer patients, who were randomly selected from representative hospitals of 7 traditional areas in China between 1999 and 2008. A total of 3271 cases (77.7%) received adjuvant chemotherapy, 558 (13.3%) received neoadjuvant chemotherapy, and 392 (9.3%) received chemotherapy for metastatic disease. In the adjuvant setting, higher percentage of patients with younger age, advanced stage, hormone receptor (HR) negative or HER2 positive disease received chemotherapy (P<0.001). The use of CMF (cyclophosphamide, methotrexate and 5-fluorouracil) in adjuvant chemotherapy decreased significantly from 1999 to 2008, while the use of anthracycline-based (without taxanes) regimens increased in the first 5 years, followed by increased use of regimens containing both anthracyclines and taxanes. Women with locally advanced disease received more neoadjuvant chemotherapy. The percentage of neoadjuvant regimens containing anthracyclines and taxanes increased during this period. In first-line chemotherapy of metastatic disease, 87.5% of cases received combined chemotherapy, and platinum-based regimens were also major choices aside from anthracyclines and taxanes. In second-line chemotherapy, 80.3% received combined chemotherapy, and the combination of taxane and platinum was the most common choice. In conclusion, major changes have taken place in breast cancer chemotherapy in China during this 10-year interval, which reflected the incorporation of key evidence and guidelines into Chinese medical practice.

Keywords: PDAC; SREBP; diabetes; insulin; transgelin2.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST No potential conflicts of interest were disclosed.

Figures

Figure 1
Figure 1. Percentage of adjuvant chemotherapy regimens for breast cancer treatment from 1999 to 2008 (after normalization of age)
Figure 2
Figure 2. Percentage of doxorubicin and epirubicin in adjuvant chemotherapy regimens containing anthracyclines from 1999 to 2008
Figure 3
Figure 3. Percentage of neoadjuvant chemotherapy regimens for breast cancer treatment from 1999 to 2008
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995;332:901–6. - PubMed
    1. Lopez-Tarruella S, Martin M. Recent advances in systemic therapy: advances in adjuvant systemic chemotherapy of early breast cancer. Breast Cancer Res. 2009;11:204. - PMC - PubMed
    1. Ring AE, Ellis PA. Taxanes in the treatment of early breast cancer. Cancer Treat Rev. 2005;31:618–27. - PubMed
    1. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976–83. - PubMed
    1. Tkaczuk KH. Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer. Clin Ther. 2009;31(Pt 2):2273–89. - PubMed